Cinnarizine Sopharma tablets of 25 mg, blister of 50 pcs

Cinnarizine improves cerebral and peripheral blood circulation by inhibiting the action of endogenous vasoconstrictor substances and the penetration of calcium ions into cells by blocking slow potential-dependent calcium channels.

It has a high affinity for smooth muscle cells of brain vessels. Cinnarizine improves insufficient microcirculation by increasing the ability of erythrocytes to deform, improves the rheological properties of blood. Increases resistance of cells to hypoxia. Has no cardiodepressant effect. Suppresses nystagmus and other manifestations of vestibular disorders, reduces the excitability of the labyrinth. It has a certain antihistamine effect.

It is relatively slowly absorbed in the gastrointestinal tract. C _max in blood plasma is reached 1-3 hours after oral administration. This indicator has significant individual differences. It binds to blood plasma proteins up to 80%, with erythrocytes – up to 13%. The distribution in tissues is more intense, by the 4th hour after application, high concentrations are determined in the liver and lungs, myocardium, and brain. It is intensively metabolized, mainly by N-dealkylation.

T _½ is 3-6 h. Excreted with feces and urine in the form of metabolites.

Symptomatic treatment of labyrinthine and vestibular disorders of vascular origin, Meniere’s disease.

Prevention of motion sickness.

Used in adults and children over 12 years old. tablets are taken orally after a meal, drinking a sufficient amount of water.

Symptomatic treatment of labyrinthine and vestibular disorders of vascular origin, Meniere’s disease. The daily dose is 75 mg (3 tablets), take 1 tablet 3 times a day.

Prevention of motion sickness. Take 1 tablet 2 hours before departure and 1 tablet every next 8 hours on the road.

Do not exceed recommended doses.

The maximum daily dose for adults is 225 mg (9 tablets).

The effectiveness of the treatment depends on the individual dosage regimen and the sufficient duration of the treatment course.

Hypersensitivity to the active substance or any component of the drug. the drug is contraindicated during pregnancy and breastfeeding. not used in children under 12 years of age.

The most common adverse reactions are: drowsiness, gastrointestinal discomfort, which, as a rule, do not last long and can easily be prevented by selecting the optimal dose.

Other, less common side reactions: vascular disorders – arterial hypotension; neurological disorders – headache; in elderly patients who have been taking cinnarizine in higher doses for a long time, the appearance of extrapyramidal symptoms (tremor, disorientation, imbalance), including Parkinson’s syndrome, is possible; gastrointestinal disorders – dry mouth; hepatobiliary disorders – extremely rarely cholestatic jaundice; disorders of the skin and subcutaneous tissue – hypersensitivity reactions, in very rare cases lichen planus and lupus erythematosus skin symptoms; metabolic disorders – increased sweating, in rare cases, weight gain.

Like other antihistamines, cinnarizine can cause stomach irritation; use of the drug after a meal reduces it.

In Parkinson’s disease, cinnarizine should be prescribed only if the benefit of treatment exceeds the possible risk of worsening the course of this disease.

With caution, the drug should be used in elderly patients, in the presence of clinical symptoms (or indications in the family history) of extrapyramidal disorders.

In persons prone to hypotensive reactions, it is necessary to monitor blood pressure during treatment.

1 tablet of the medicinal product contains 63.12 mg of lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption syndrome should not use this drug.

The drug contains an auxiliary substance – wheat starch – and its use can be dangerous for patients with celiac disease (gluten enteropathy).

The period of pregnancy and breastfeeding. The drug is not used during pregnancy and breastfeeding. During breastfeeding, it is recommended to stop using the drug or stop breastfeeding.

Children. Do not use in children under 12 years of age.

The ability to influence the speed of reaction when driving a motor vehicle or working with other mechanisms. When using the drug, especially at the beginning of treatment, drowsiness may occur. Therefore, it is possible to prescribe the drug to drivers and persons whose work involves a high speed of mental and physical reactions only after an accurate assessment of the probable risk.

Simultaneous use of cinnarizine with alcohol, CNS depressants or tricyclic antidepressants causes mutual potentiation of their effects.

Cinnarizine enhances the effect of nootropic sedative, hypotensive and vasodilator drugs. Reduces the effect of hypertensive drugs.

The presence of an antihistaminic effect of cinnarizine can lead to false negative results when conducting dermatological diagnostic tests to determine hypersensitivity. This necessitates the suspension of Cinnarizine treatment at least 4 days before the tests.

Cinnarizine can cause a false positive reaction in tests during doping control in athletes.

Symptoms: vomiting, drowsiness, hypotension, tremors, coma.

Treatment with the drug is stopped and measures are taken to quickly remove the drug from the body (gastric lavage, activated charcoal), as well as symptomatic remedies. There is no specific antidote.

In a dry place protected from light at a temperature not higher than 25 °C.